Browsing Tag
Pete Smith
1 post
Racura Oncology (ASX: RAC) stock up 12.21% as MYC silencing data builds case for bisantrene relaunch
MYC is the undruggable cancer gene. Racura Oncology (ASX: RAC) says bisantrene silences it via G4 stabilisation. Three clinical trials, A$19m cash, and a 2027 inflection ahead.